RNT Medical College, Udaipur has announced that MB General Hospital will not use Methylene Blue medicine for COVID or Mucormycosis treatment, without the permission of Drug Controller General of India (DGCI).

Principal Dr. Lakhan Poswal informed that a committee of 3 Doctors has been set up. They will coordinate with the Central Drug Standard Control Organization and only after getting their approval, the adminsitrationn of Methylene Blue medicine for the treatment will start.

The committee members will include:

• Dr. Soochi Goyal (HOD Biochemistry)
• Dr. Navneet Mathur (HOD ENT)
• Dr. Neera Samar (Department of Medicine)

The committee has been given a deadline of 5 days to get the permission.

Brief idea about methylene blue

The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue color) has been used in many different areas of clinical medicine, ranging from malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied for the treatment of COVID-19 according to the scientific evidences. https://clinicaltrials.gov/ct2/show/NCT04370288